In the News
September 6, 2019
Chimeron Bio Announces Appointment of Dr. Afshin Safavi to Chairman of the Board
Dr. Afshin Safavi is a seasoned entrepreneur and investor in biotechnology, pharmaceutical, IT-technology.
Combining our first-in-class platform & the science of synthetic genomics to transform RNA therapy.
Chimeron Bio is building a portfolio of self-amplifying RNA therapeutics to bring more effective gene therapies and personalized medicines to patients.
How we do it
Our ChaESAR Platform
Chimeron Bio’s unique ChaESAR platform leverages chimera encased self-amplifying RNA (saRNA) to achieve superior expression and broader dynamic range compared to other leading messenger RNA (mRNA) technologies.
Why we do it
Building on the Modern Science of RNA to Create First-in-Class saRNA Drugs for Patients with Unmet Needs
We are developing a compelling portfolio of innovative and personalized saRNA-based medicines for people with serious diseases including cancer, infectious diseases, and rare genetic disorders, using our technology to achieve superior patient response at a lower dose.
The Latest from Chimeron Bio
From Our Blog
September 9, 2019
Why Philadelphia for Chimeron Bio
For an early-stage company such as Chimeron Bio, with an innovative gene therapy approach, the right ecosystem is pivotal for its growth and development.
Are you passionate about science and making an impact?
We’re looking for talented individuals to join our team.